Search

My top investment theme for 2018 has to do with a corporate America spending spree thanks to lower tax rates and a sudden influx of cash.

So what do I tell people who ask why they should buy individual stocks? First, you can make money by buying stocks.

It’s long overdue, but there’s finally a new age in women’s healthcare, and that benefits one healthcare stock in particular.

Which characteristic has led me to some of the fastest growing stocks in the market going back many years? Triple-digit sales growth.

Today I want to discuss an energy sector that enjoyed some big news this week—natural gas.

The long-feared and yet still wholly unexpected “Brexit” is happening, and panic has fully engulfed the world share market. Here’s how to navigate the choppy waters.

Yesterday’s big rally in the Nasdaq was enough to reignite bullish spirits but it was not a clear signal that it is time back up the truck on growth stocks just yet. While I side with those who say the pullback has opened up opportunities for fresh buying in many beaten down names, I think the chances of a snapback rally in many of the highest multiple growth stocks, then a follow through to new highs within a few weeks, is unlikely.

This week we had two companies reporting earnings, one reports next week, and the earnings deluge starts the following week with at least seven companies reporting.

After a couple of months of strong action, the long-awaited market pullback has gotten underway, and not surprisingly it’s been a bit of a doozy.

With markets expecting a deal right around the corner, the Trump administration signaled its frustration by threatening to raise tariffs on roughly $200 billion of Chinese imports to 25%, from 10%, last Friday.

McKinsey & Company is a big consulting firm—9,000 consultants and 2,000 researchers around the world—that companies hire when they need advice. I get research reports from McKinsey every once in a while, and they’re usually beautifully designed, well written and interesting in an abstract kind of way. The report that reached my email in-box on Thursday had the intriguing title: “Why investors may need to lower their sights.” (Note how the avoidance of Capital Letters makes things a little edgier; that’s the McKinsey Difference!) It took seven people to write this little piece of analysis, so you know it must contain really valuable information.

My stock picking criteria is multi-faceted, but my favorite strategy involves a simple data point that has helped me beat the market for 11 years running.

Tesla and Elon Musk have taken a lot of heat lately. But let’s compare TSLA stock to the charts of Volkswagen (VWAPY) and Fiat Chrysler (FCAU).

Drug manufacturing is a $160 billion market, with $30 billion in profits. By 2020, sales are expected to top $170 billion. That bodes well for drug stocks.

ASML’s earnings on October 15 may confirm surging AI chip demand—its bookings and outlook could decide whether the semiconductor rally has more room to run.

Dividend Aristocrats remain a reliable way for income investors to earn high - and growing - yields. Here are three of the top Dividend Aristocrats for 2025, according to Sure Dividend.

Our readers offer their reactions to recent articles about the cannabis investing environment and banning government leaders from trading individual stocks.

The unwinding of the Japanese carry trade exacerbated an otherwise normal pullback in stocks and dragged down small caps. But don’t lose track of the bullish case moving forward.